Tumour hypoxia induces a metabolic shift causing acidosis: A common feature in cancer

Journal of Cellular and Molecular Medicine

Volumn 14, Issue 4, 2010, Pages 771-794

  Chiche, Johanna ^a   Brahimi Horn, M Christiane ^a   Pouysségur, Jacques ^a  

^a UNIVERSITÉ CÔTE D'AZUR   (France)

Author keywords

Acidosis; Carbonic anhydrases; Energy production; Glycolysis; Hypoxia inducible factor; Monocarboxylate transporters; Na+ H+ exchanger; Oncogenes activation; PH homeostasis; Tumour microenvironment

Indexed keywords

ACIDOSIS; ARTICLE; CELL HYPOXIA; CELL TRANSFORMATION; ENERGY METABOLISM; HUMAN; METABOLISM; NEOPLASM; PATHOLOGY; PH;

ACIDOSIS; CELL HYPOXIA; CELL TRANSFORMATION, NEOPLASTIC; ENERGY METABOLISM; HUMANS; HYDROGEN-ION CONCENTRATION; NEOPLASMS;

EID: 77953935500     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2009.00994.x     Document Type: Article

References (268)

1. Lindner D, Raghavan D. Intra-tumoural extra-cellular pH: a useful parameter of response to chemotherapy in syngeneic tumour lines. Br J Cancer. 2009, 100:1287-91.
2. Gillies RJ, Alger JR, den Hollander JA. Intracellular pH measured by NMR: methods and results. Kroc Found Ser. 1981, 15:79-104.
3. Gillies RJ, Raghunand N, Garcia-Martin ML. pH imaging. A review of pH measurement methods and applications in cancers. IEEE Eng Med Biol Mag. 2004, 23:57-64.
4. Gillies RJ, Liu Z, Bhujwalla Z. 31P-MRS measurements of extracellular pH of tumors using 3-aminopropylphosphonate. Am J Physiol 1994, 267:C195-203.
5. Gillies RJ, Robey I, Gatenby RA. Causes and consequences of increased glucose metabolism of cancers. J Nucl Med 2008, 49:24S-42S.
6. Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nat Rev Cancer. 2004, 4:891-9.
7. Stubbs M, McSheehy PM, Griffiths JR. Causes and consequences of tumour acidity and implications for treatment. Mol Med Today. 2000, 6:15-9.
8. Griffiths JR. Are cancer cells acidic? Br J Cancer. 1991, 64:425-7.
9. Vaupel P, Kallinowski F, Okunieff P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res. 1989, 49:6449-65.
10. Pouyssegur J, Dayan F, Mazure NM. Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature. 2006, 441:437-43.
11. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer. 2003, 3:721-32.
12. Roos A, Boron WF. Intracellular pH. Physiol Rev. 1981, 61:296-434.
13. Pouyssegur J, Sardet C, Franchi A. A specific mutation abolishing Na+/H+ antiport activity in hamster fibroblasts precludes growth at neutral and acidic pH. Proc Natl Acad Sci USA. 1984, 81:4833-7.
14. Chambard JC, Pouyssegur J. Intracellular pH controls growth factor-induced ribosomal protein S6 phosphorylation and protein synthesis in the G0-G1 transition of fibroblasts. Exp Cell Res. 1986, 164:282-94.
15. Matsuyama S, Llopis J, Deveraux QL. Changes in intramitochondrial and cytosolic pH: early events that modulate caspase activation during apoptosis. Nat Cell Biol. 2000, 2:318-25.
16. Sardet C, Franchi A, Pouyssegur J. Molecular cloning, primary structure, and expression of the human growth factor-activatable Na+/H+ antiporter. Cell. 1989, 56:271-80.
17. Counillon L, Pouyssegur J. The expanding family of eucaryotic Na(+)/H(+) exchangers. J Biol Chem. 2000, 275:1-4.
18. Martinez-Zaguilan R, Lynch RM, Martinez GM. Vacuolar-type H(+)-ATPases are functionally expressed in plasma membranes of human tumor cells. Am J Physiol 1993, 265:C1015-29.
19. Halestrap AP, Meredith D. The SLC16 gene family-from monocarboxylate transporters (MCTs) to aromatic amino acid transporters and beyond. Pflugers Arch. 2004, 447:619-28.
20. Alper SL. Molecular physiology of SLC4 anion exchangers. Exp Physiol. 2006, 91:153-61.
21. Romero MF, Fulton CM, Boron WF. The SLC4 family of HCO 3 - transporters. Pflugers Arch. 2004, 447:495-509.
22. Ullah MS, Davies AJ, Halestrap AP. The plasma membrane lactate transporter MCT4, but not MCT1, is up-regulated by hypoxia through a HIF-1alpha-dependent mechanism. J Biol Chem. 2006, 281:9030-7.
23. Ivanov S, Liao SY, Ivanova A. Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer. Am J Pathol. 2001, 158:905-19.
24. Chiche J, Ilc K, Laferriere J. Hypoxia-inducible carbonic anhydrase IX and XII promote tumor cell growth by counteracting acidosis through the regulation of the intracellular pH. Cancer Res. 2009, 69:358-68.
25. Glunde K, Guggino SE, Solaiyappan M. Extracellular acidification alters lysosomal trafficking in human breast cancer cells. Neoplasia. 2003, 5:533-45.
26. Martinez-Zaguilan R, Seftor EA, Seftor RE. Acidic pH enhances the invasive behavior of human melanoma cells. Clin Exp Metastasis. 1996, 14:176-86.
27. Lardner A. The effects of extracellular pH on immune function. J Leukoc Biol. 2001, 69:522-30.
28. Fischer K, Hoffmann P, Voelkl S. Inhibitory effect of tumor cell-derived lactic acid on human T cells. Blood. 2007, 109:3812-9.
29. Sauvant C, Nowak M, Wirth C. Acidosis induces multi-drug resistance in rat prostate cancer cells (AT1) in vitro and in vivo by increasing the activity of the p-glycoprotein via activation of p38. Int J Cancer. 2008, 123:2532-42.
30. Morita T. Low pH leads to sister-chromatid exchanges and chromosomal aberrations, and its clastogenicity is S-dependent. Mutat Res. 1995, 334:301-8.
31. Gerweck LE, Seetharaman K. Cellular pH gradient in tumor versus normal tissue: potential exploitation for the treatment of cancer. Cancer Res. 1996, 56:1194-8.
32. Gerweck LE. The pH difference between tumor and normal tissue offers a tumor specific target for the treatment of cancer. Drug Resist Updat. 2000, 3:49-50.
33. Chandrashekar J, Yarmolinsky D, von Buchholtz L. The taste of carbonation. Science. 2009, 326:443-5.
34. Wohlhueter RM, Plagemann PG. Hexose transport and phosphorylation by Novikoff rat hepatoma cells as function of extracellular pH. J Biol Chem. 1981, 256:869-75.
35. Buckwitz D, Jacobasch G, Gerth C. A kinetic model of phosphofructokinase from Plasmodium berghei. Influence of ATP and fructose-6-phosphate. Mol Biochem Parasitol. 1988, 27:225-32.
36. Spriet LL. Phosphofructokinase activity and acidosis during short-term tetanic contractions. Can J Physiol Pharmacol. 1991, 69:298-304.
37. Gluck S, Nelson R. The role of the V-ATPase in renal epithelial H+ transport. J Exp Biol. 1992, 172:205-18.
38. Gluck SL, Nelson RD, Lee BS. Biochemistry of the renal V-ATPase. J Exp Biol. 1992, 172:219-29.
39. Merezhinskaya N, Ogunwuyi SA, Mullick FG. Presence and localization of three lactic acid transporters (MCT1, -2, and -4) in separated human granulocytes, lymphocytes, and monocytes. J Histochem Cytochem. 2004, 52:1483-93.
40. Pilegaard H, Domino K, Noland T. Effect of high-intensity exercise training on lactate/H+ transport capacity in human skeletal muscle. Am J Physiol 1999, 276:E255-61.
41. Pilegaard H, Terzis G, Halestrap A. Distribution of the lactate/H+ transporter isoforms MCT1 and MCT4 in human skeletal muscle. Am J Physiol 1999, 276:E843-8.
42. Boron WF. Sodium-coupled bicarbonate transporters. Jop. 2001, 2:176-81.
43. Vaughan-Jones RD, Spitzer KW. Role of bicarbonate in the regulation of intracellular pH in the mammalian ventricular myocyte. Biochem Cell Biol. 2002, 80:579-96.
44. Khalifah RG. The carbon dioxide hydration activity of carbonic anhydrase. I. Stop-flow kinetic studies on the native human isoenzymes B and C. J Biol Chem. 1971, 246:2561-73.
45. Brant SR, Yun CH, Donowitz M. Cloning, tissue distribution, and functional analysis of the human Na+/N+ exchanger isoform, NHE3. Am J Physiol 1995, 269:C198-206.
46. Praetorius J, Andreasen D, Jensen BL. NHE1, NHE2, and NHE3 contribute to regulation of intracellular pH in murine duodenal epithelial cells. Am J Physiol Gastrointest Liver Physiol 2000, 278:G197-206.
47. Tse CM, Brant SR, Walker MS. Cloning and sequencing of a rabbit cDNA encoding an intestinal and kidney-specific Na+/H+ exchanger isoform (NHE-3). J Biol Chem. 1992, 267:9340-6.
48. Wang Z, Orlowski J, Shull GE. Primary structure and functional expression of a novel gastrointestinal isoform of the rat Na/H exchanger. J Biol Chem. 1993, 268:11925-8.
49. Attaphitaya S, Park K, Melvin JE. Molecular cloning and functional expression of a rat Na+/H+ exchanger (NHE5) highly expressed in brain. J Biol Chem. 1999, 274:4383-8.
50. Goyal S, Vanden Heuvel G, Aronson PS. Renal expression of novel Na+/H+ exchanger isoform NHE8. Am J Physiol Renal Physiol 2003, 284:F467-73.
51. Nakamura N, Tanaka S, Teko Y. Four Na+/H+ exchanger isoforms are distributed to Golgi and post-Golgi compartments and are involved in organelle pH regulation. J Biol Chem. 2005, 280:1561-72.
52. Numata M, Orlowski J. Molecular cloning and characterization of a novel (Na+,K+)/H+ exchanger localized to the trans-Golgi network. J Biol Chem. 2001, 276:17387-94.
53. Paris S, Pouyssegur J. Growth factors activate the Na+/H+ antiporter in quiescent fibroblasts by increasing its affinity for intracellular H+. J Biol Chem. 1984, 259:10989-94.
54. Pouyssegur J, Chambard JC, Franchi A. Growth factor activation of an amiloride-sensitive Na+/H+ exchange system in quiescent fibroblasts: coupling to ribosomal protein S6 phosphorylation. Proc Natl Acad Sci USA. 1982, 79:3935-9.
55. Pouyssegur J, Franchi A, L'Allemain G. Cytoplasmic pH, a key determinant of growth factor-induced DNA synthesis in quiescent fibroblasts. FEBS Lett. 1985, 190:115-9.
56. Franchi A, Perucca-Lostanlen D. Functional expression of a human Na+/H+ antiporter gene transfected into antiporter-deficient mouse L cells. Proc Natl Acad Sci USA. 1986, 83:9388-92.
57. Lagarde AE, Franchi AJ, Paris S. Effect of mutations affecting Na+: H+ antiport activity on tumorigenic potential of hamster lung fibroblasts. J Cell Biochem. 1988, 36:249-60.
58. Pouyssegur J, Franchi A, Pages G. pHi, aerobic glycolysis and vascular endothelial growth factor in tumour growth. Novartis Found Symp. 2001, 240:186-96.
59. Rotin D, Steele-Norwood D, Grinstein S. Requirement of the Na+/H+ exchanger for tumor growth. Cancer Res. 1989, 49:205-11.
60. Franchi A, Silvestre P, Pouyssegur J. A genetic approach to the role of energy metabolism in the growth of tumor cells: tumorigenicity of fibroblast mutants deficient either in glycolysis or in respiration. Int J Cancer. 1981, 27:819-27.
61. Pouyssegur J, Franchi A, Salomon JC. Isolation of a Chinese hamster fibroblast mutant defective in hexose transport and aerobic glycolysis: its use to dissect the malignant phenotype. Proc Natl Acad Sci USA. 1980, 77:2698-701.
62. Newell K, Franchi A, Pouyssegur J. Studies with glycolysis-deficient cells suggest that production of lactic acid is not the only cause of tumor acidity. Proc Natl Acad Sci USA. 1993, 90:1127-31.
63. L'Allemain G, Paris S, Pouyssegur J. Role of a Na+-dependent Cl-/HCO3- exchange in regulation of intracellular pH in fibroblasts. J Biol Chem. 1985, 260:4877-83.
64. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000, 100:57-70.
65. Warburg O. On respiratory impairment in cancer cells. Science. 1956, 124:269-70.
66. Larson SM. Positron emission tomography-based molecular imaging in human cancer: exploring the link between hypoxia and accelerated glucose metabolism. Clin Cancer Res. 2004, 10:2203-4.
67. Funes JM, Quintero M, Henderson S. Transformation of human mesenchymal stem cells increases their dependency on oxidative phosphorylation for energy production. Proc Natl Acad Sci USA. 2007, 104:6223-8.
68. Fang JS, Gillies RD, Gatenby RA. Adaptation to hypoxia and acidosis in carcinogenesis and tumor progression. Semin Cancer Biol. 2008, 18:330-7.
69. Elstrom RL, Bauer DE, Buzzai M. Akt stimulates aerobic glycolysis in cancer cells. Cancer Res. 2004, 64:3892-9.
70. Kondoh H, Lleonart ME, Gil J. Glycolytic enzymes can modulate cellular life span. Cancer Res. 2005, 65:177-85.
71. Bensaad K, Tsuruta A, Selak MA. TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell. 2006, 126:107-20.
72. Matoba S, Kang JG, Patino WD. p53 regulates mitochondrial respiration. Science. 2006, 312:1650-3.
73. Xu RH, Pelicano H, Zhang H. Synergistic effect of targeting mTOR by rapamycin and depleting ATP by inhibition of glycolysis in lymphoma and leukemia cells. Leukemia. 2005, 19:2153-8.
74. Plas DR, Thompson CB. Akt-dependent transformation: there is more to growth than just surviving. Oncogene. 2005, 24:7435-42.
75. Rathmell JC, Fox CJ, Plas DR. Akt-directed glucose metabolism can prevent Bax conformation change and promote growth factor-independent survival. Mol Cell Biol. 2003, 23:7315-28.
76. Blum R, Jacob-Hirsch J, Amariglio N. Ras inhibition in glioblastoma down-regulates hypoxia-inducible factor-1alpha, causing glycolysis shutdown and cell death. Cancer Res. 2005, 65:999-1006.
77. Osthus RC, Shim H, Kim S. Deregulation of glucose transporter 1 and glycolytic gene expression by c-Myc. J Biol Chem. 2000, 275:21797-800.
78. Shim H, Dolde C, Lewis BC. c-Myc transactivation of LDH-A: implications for tumor metabolism and growth. Proc Natl Acad Sci USA. 1997, 94:6658-63.
79. Wise DR, DeBerardinis RJ, Mancuso A. Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc Natl Acad Sci USA. 2008, 105:18782-7.
80. Eagle H. Nutrition needs of mammalian cells in tissue culture. Science. 1955, 122:501-14.
81. Chen MK, Espat NJ, Bland KI. Influence of progressive tumor growth on glutamine metabolism in skeletal muscle and kidney. Ann Surg. 1993, 217:655-66. discussion 66-7
82. Klimberg VS, McClellan JL. Claude H. Organ, Jr. Honorary Lectureship. Glutamine, cancer, and its therapy. Am J Surg. 1996, 172:418-24.
83. DeBerardinis RJ, Mancuso A, Daikhin E. Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc Natl Acad Sci USA. 2007, 104:19345-50.
84. Kaplan DL, Boron WF. Long-term expression of c-H-ras stimulates Na-H and Na(+)-dependent Cl-HCO3 exchange in NIH-3T3 fibroblasts. J Biol Chem. 1994, 269:4116-24.
85. Gillies RJ, Martinez-Zaguilan R, Martinez GM. Tumorigenic 3T3 cells maintain an alkaline intracellular pH under physiological conditions. Proc Natl Acad Sci USA. 1990, 87:7414-8.
86. Perona R, Serrano R. Increased pH and tumorigenicity of fibroblasts expressing a yeast proton pump. Nature. 1988, 334:438-40.
87. Reshkin SJ, Bellizzi A, Caldeira S. Na+/H+ exchanger-dependent intracellular alkalinization is an early event in malignant transformation and plays an essential role in the development of subsequent transformation-associated phenotypes. FASEB J. 2000, 14:2185-97.
88. Cardone RA, Busco G, Greco MR. HPV16 E7-dependent transformation activates NHE1 through a PKA-RhoA-induced inhibition of p38alpha. PLoS One. 2008, 3:e3529.
89. Kunz M, Ibrahim SM. Molecular responses to hypoxia in tumor cells. Mol Cancer. 2003, 2:23.
90. Brahimi-Horn MC, Pouyssegur J. Harnessing the hypoxia-inducible factor in cancer and ischemic disease. Biochem Pharmacol. 2007, 73:450-7.
91. Brahimi-Horn MC, Pouyssegur J. The hypoxia-inducible factor and tumor progression along the angiogenic pathway. Int Rev Cytol. 2005, 242:157-213.
92. Schofield CJ, Ratcliffe PJ. Oxygen sensing by HIF hydroxylases. Nat Rev Mol Cell Biol. 2004, 5:343-54.
93. Berra E, Richard DE, Gothie E. HIF-1-dependent transcriptional activity is required for oxygen-mediated HIF-1alpha degradation. FEBS Lett. 2001, 491:85-90.
94. Schofield CJ, Ratcliffe PJ. Signalling hypoxia by HIF hydroxylases. Biochem Biophys Res Commun. 2005, 338:617-26.
95. Jaakkola P, Mole DR, Tian YM. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science. 2001, 292:468-72.
96. Lando D, Peet DJ, Gorman JJ. FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor. Genes Dev. 2002, 16:1466-71.
97. Hewitson KS, McNeill LA, Riordan MV. Hypoxia-inducible factor (HIF) asparagine hydroxylase is identical to factor inhibiting HIF (FIH) and is related to the cupin structural family. J Biol Chem. 2002, 277:26351-5.
98. Lee C, Kim SJ, Jeong DG. Structure of human FIH-1 reveals a unique active site pocket and interaction sites for HIF-1 and von Hippel-Lindau. J Biol Chem. 2003, 278:7558-63.
99. Bilton R, Trottier E, Pouyssegur J. ARDent about acetylation and deacetylation in hypoxia signalling. Trends Cell Biol. 2006, 16:616-21.
100. Brahimi-Horn C, Mazure N, Pouyssegur J. Signalling via the hypoxia-inducible factor-1alpha requires multiple posttranslational modifications. Cell Signal. 2005, 17:1-9.
101. Koivunen P, Hirsila M, Gunzler V. Catalytic properties of the asparaginyl hydroxylase (FIH) in the oxygen sensing pathway are distinct from those of its prolyl 4-hydroxylases. J Biol Chem. 2004, 279:9899-904.
102. Kallio PJ, Okamoto K, O'Brien S. Signal transduction in hypoxic cells: inducible nuclear translocation and recruitment of the CBP/p300 coactivator by the hypoxia-inducible factor-1alpha. EMBO J. 1998, 17:6573-86.
103. Dang CV. The interplay between MYC and HIF in the Warburg effect. Ernst Schering Found Symp Proc 2007:35-53.
104. Hammond EM, Giaccia AJ. The role of p53 in hypoxia-induced apoptosis. Biochem Biophys Res Commun. 2005, 331:718-25.
105. Shafee N, Kaluz S, Ru N. PI3K/Akt activity has variable cell-specific effects on expression of HIF target genes, CA9 and VEGF, in human cancer cell lines. Cancer Lett. 2009, 282:109-15.
106. Manalo DJ, Rowan A, Lavoie T. Transcriptional regulation of vascular endothelial cell responses to hypoxia by HIF-1. Blood. 2005, 105:659-69.
107. Dayan F, Roux D, Brahimi-Horn MC. The oxygen sensor factor-inhibiting hypoxia-inducible factor-1 controls expression of distinct genes through the bifunctional transcriptional character of hypoxia-inducible factor-1alpha. Cancer Res. 2006, 66:3688-98.
108. Gordan JD, Simon MC. Hypoxia-inducible factors: central regulators of the tumor phenotype. Curr Opin Genet Dev. 2007, 17:71-7.
109. Ratcliffe PJ. HIF-1 and HIF-2: working alone or together in hypoxia? J Clin Invest. 2007, 117:862-5.
110. Makino Y, Cao R, Svensson K. Inhibitory PAS domain protein is a negative regulator of hypoxia-inducible gene expression. Nature. 2001, 414:550-4.
111. Bell EL, Chandel NS. Mitochondrial oxygen sensing: regulation of hypoxia-inducible factor by mitochondrial generated reactive oxygen species. Essays Biochem. 2007, 43:17-27.
112. Chavez A, Miranda LF, Pichiule P. Mitochondria and hypoxia-induced gene expression mediated by hypoxia-inducible factors. Ann N Y Acad Sci. 2008, 1147:312-20.
113. Gerald D, Berra E, Frapart YM. JunD reduces tumor angiogenesis by protecting cells from oxidative stress. Cell. 2004, 118:781-94.
114. Qutub AA, Popel AS. Reactive oxygen species regulate hypoxia-inducible factor 1alpha differentially in cancer and ischemia. Mol Cell Biol. 2008, 28:5106-19.
115. Milner PI, Wilkins RJ, Gibson JS. The role of mitochondrial reactive oxygen species in pH regulation in articular chondrocytes. Osteoarthritis Cartilage. 2007, 15:735-42.
116. Shimoda LA, Fallon M, Pisarcik S. HIF-1 regulates hypoxic induction of NHE1 expression and alkalinization of intracellular pH in pulmonary arterial myocytes. Am J Physiol Lung Cell Mol Physiol 2006, 291:L941-9.
117. Kim JW, Tchernyshyov I, Semenza GL. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab. 2006, 3:177-85.
118. Papandreou I, Cairns RA, Fontana L. HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. Cell Metab. 2006, 3:187-97.
119. Fukuda R, Zhang H, Kim JW. HIF-1 regulates cytochrome oxidase subunits to optimize efficiency of respiration in hypoxic cells. Cell. 2007, 129:111-22.
120. Natsuizaka M, Ozasa M, Darmanin S. Synergistic up-regulation of Hexokinase-2, glucose transporters and angiogenic factors in pancreatic cancer cells by glucose deprivation and hypoxia. Exp Cell Res. 2007, 313:3337-48.
121. Kim JW, Dang CV. Multifaceted roles of glycolytic enzymes. Trends Biochem Sci. 2005, 30:142-50.
122. Fantin VR, St-Pierre J, Leder P. Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell. 2006, 9:425-34.
123. Pelicano H, Martin DS, Xu RH. Glycolysis inhibition for anticancer treatment. Oncogene. 2006, 25:4633-46.
124. Gutierrez G. A mathematical model of tissue-blood carbon dioxide exchange during hypoxia. Am J Respir Crit Care Med. 2004, 169:525-33.
125. Svastova E, Hulikova A, Rafajova M. Hypoxia activates the capacity of tumor-associated carbonic anhydrase IX to acidify extracellular pH. FEBS Lett. 2004, 577:439-45.
126. Robertson N, Potter C, Harris AL. Role of carbonic anhydrase IX in human tumor cell growth, survival, and invasion. Cancer Res. 2004, 64:6160-5.
127. Swietach P, Wigfield S, Cobden P. Tumor-associated carbonic anhydrase 9 spatially coordinates intracellular pH in three-dimensional multicellular growths. J Biol Chem. 2008, 283:20473-83.
128. Mekhail K, Gunaratnam L, Bonicalzi ME. HIF activation by pH-dependent nucleolar sequestration of VHL. Nat Cell Biol. 2004, 6:642-7.
129. Willam C, Warnecke C, Schefold JC. Inconsistent effects of acidosis on HIF-alpha protein and its target genes. Pflugers Arch. 2006, 451:534-43.
130. Xu L, Fidler IJ. Acidic pH-induced elevation in interleukin 8 expression by human ovarian carcinoma cells. Cancer Res. 2000, 60:4610-6.
131. Fukumura D, Xu L, Chen Y. Hypoxia and acidosis independently up-regulate vascular endothelial growth factor transcription in brain tumors in vivo. Cancer Res. 2001, 61:6020-4.
132. Shi Q, Le X, Wang B. Regulation of vascular endothelial growth factor expression by acidosis in human cancer cells. Oncogene. 2001, 20:3751-6.
133. Bischoff DS, Zhu JH, Makhijani NS. Acidic pH stimulates the production of the angiogenic CXC chemokine, CXCL8 (interleukin-8), in human adult mesenchymal stem cells via the extracellular signal-regulated kinase, p38 mitogen-activated protein kinase, and NF-kappaB pathways. J Cell Biochem. 2008, 104:1378-92.
134. van Uden P, Kenneth NS, Rocha S. Regulation of hypoxia-inducible factor-1alpha by NF-kappaB. Biochem J. 2008, 412:477-84.
135. Ryan S, McNicholas WT, Taylor CT. A critical role for p38 map kinase in NF-kappaB signaling during intermittent hypoxia/reoxygenation. Biochem Biophys Res Commun. 2007, 355:728-33.
136. Barbera MJ, Puig I, Dominguez D. Regulation of Snail transcription during epithelial to mesenchymal transition of tumor cells. Oncogene. 2004, 23:7345-54.
137. Moellering RE, Black KC, Krishnamurty C. Acid treatment of melanoma cells selects for invasive phenotypes. Clin Exp Metastasis. 2008, 25:411-25.
138. Rios EJ, Fallon M, Wang J. Chronic hypoxia elevates intracellular pH and activates Na+/H+ exchange in pulmonary arterial smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 2005, 289:L867-74.
139. Gatenby RA, Smallbone K, Maini PK. Cellular adaptations to hypoxia and acidosis during somatic evolution of breast cancer. Br J Cancer. 2007, 97:646-53.
140. Reshkin SJ, Bellizzi A, Albarani V. Phosphoinositide 3-kinase is involved in the tumor-specific activation of human breast cancer cell Na(+)/H(+) exchange, motility, and invasion induced by serum deprivation. J Biol Chem. 2000, 275:5361-9.
141. Stock C, Gassner B, Hauck CR. Migration of human melanoma cells depends on extracellular pH and Na+/H+ exchange. J Physiol. 2005, 567:225-38.
142. Denker SP, Barber DL. Cell migration requires both ion translocation and cytoskeletal anchoring by the Na-H exchanger NHE1. J Cell Biol. 2002, 159:1087-96.
143. Supuran CT. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nat Rev Drug Discov. 2008, 7:168-81.
144. Pastorek J, Pastorekova S, Callebaut I. Cloning and characterization of MN, a human tumor-associated protein with a domain homologous to carbonic anhydrase and a putative helix-loop-helix DNA binding segment. Oncogene. 1994, 9:2877-88.
145. Wykoff CC, Beasley NJ, Watson PH. Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res. 2000, 60:7075-83.
146. Opavsky R, Pastorekova S, Zelnik V. Human MN/CA9 gene, a novel member of the carbonic anhydrase family: structure and exon to protein domain relationships. Genomics. 1996, 33:480-7.
147. Barathova M, Takacova M, Holotnakova T. Alternative splicing variant of the hypoxia marker carbonic anhydrase IX expressed independently of hypoxia and tumour phenotype. Br J Cancer. 2008, 98:129-36.
148. Lau KW, Tian YM, Raval RR. Target gene selectivity of hypoxia-inducible factor-alpha in renal cancer cells is conveyed by post-DNA-binding mechanisms. Br J Cancer. 2007, 96:1284-92.
149. Jakubickova L, Biesova Z, Pastorekova S. Methylation of the CA9 promoter can modulate expression of the tumor-associated carbonic anhydrase IX in dense carcinoma cell lines. Int J Oncol. 2005, 26:1121-7.
150. Kaluz S, Kaluzova M, Liao SY. Transcriptional control of the tumor- and hypoxia-marker carbonic anhydrase 9: a one transcription factor (HIF-1) show? Biochim Biophys Acta. 2009, 1795:162-72.
151. Kaluz S, Kaluzova M, Opavsky R. Transcriptional regulation of the MN/CA 9 gene coding for the tumor-associated carbonic anhydrase IX. Identification and characterization of a proximal silencer element. J Biol Chem. 1999, 274:32588-95.
152. Kondo K, Kaelin WG. The von Hippel-Lindau tumor suppressor gene. Exp Cell Res. 2001, 264:117-25.
153. Ivanov SV, Kuzmin I, Wei MH. Down-regulation of transmembrane carbonic anhydrases in renal cell carcinoma cell lines by wild-type von Hippel-Lindau transgenes. Proc Natl Acad Sci USA. 1998, 95:12596-601.
154. Grabmaier K, AdW MC, Verhaegh GW. Strict regulation of CAIX(G250/MN) by HIF-1alpha in clear cell renal cell carcinoma. Oncogene. 2004, 23:5624-31.
155. Kaluzova M, Kaluz S, Lerman MI. DNA damage is a prerequisite for p53-mediated proteasomal degradation of HIF-1alpha in hypoxic cells and downregulation of the hypoxia marker carbonic anhydrase IX. Mol Cell Biol. 2004, 24:5757-66.
156. Kopacek J, Barathova M, Dequiedt F. MAPK pathway contributes to density- and hypoxia-induced expression of the tumor-associated carbonic anhydrase IX. Biochim Biophys Acta. 2005, 1729:41-9.
157. Kaluz S, Kaluzova M, Stanbridge EJ. The role of extracellular signal-regulated protein kinase in transcriptional regulation of the hypoxia marker carbonic anhydrase IX. J Cell Biochem. 2006, 97:207-16.
158. Sang N, Stiehl DP, Bohensky J. MAPK signaling up-regulates the activity of hypoxia-inducible factors by its effects on p300. J Biol Chem. 2003, 278:14013-9.
159. Kaluz S, Kaluzova M, Chrastina A. Lowered oxygen tension induces expression of the hypoxia marker MN/carbonic anhydrase IX in the absence of hypoxia-inducible factor 1 alpha stabilization: a role for phosphatidylinositol 3'-kinase. Cancer Res. 2002, 62:4469-77.
160. Dayan F, Bilton RL, Laferriere J. Activation of HIF-1alpha in exponentially growing cells via hypoxic stimulation is independent of the Akt/mTOR pathway. J Cell Physiol. 2009, 218:167-74.
161. van den Beucken T, Koritzinsky M, Niessen H. Hypoxia-induced expression of carbonic anhydrase 9 is dependent on the unfolded protein response. J Biol Chem 2009, 284:24204-12.
162. Ihnatko R, Kubes M, Takacova M. Extracellular acidosis elevates carbonic anhydrase IX in human glioblastoma cells via transcriptional modulation that does not depend on hypoxia. Int J Oncol. 2006, 29:1025-33.
163. Rafajova M, Zatovicova M, Kettmann R. Induction by hypoxia combined with low glucose or low bicarbonate and high posttranslational stability upon reoxygenation contribute to carbonic anhydrase IX expression in cancer cells. Int J Oncol. 2004, 24:995-1004.
164. Pastorekova S, Parkkila S, Parkkila AK. Carbonic anhydrase IX, MN/CA IX: analysis of stomach complementary DNA sequence and expression in human and rat alimentary tracts. Gastroenterology. 1997, 112:398-408.
165. Hilvo M, Rafajova M, Pastorekova S. Expression of carbonic anhydrase IX in mouse tissues. J Histochem Cytochem. 2004, 52:1313-22.
166. Kallio H, Pastorekova S, Pastorek J. Expression of carbonic anhydrases IX and XII during mouse embryonic development. BMC Dev Biol 2006, 6:22.
167. Jarvela S, Parkkila S, Bragge H. Carbonic anhydrase IX in oligodendroglial brain tumors. BMC Cancer. 2008, 8:1.
168. Niemela AM, Hynninen P, Mecklin JP. Carbonic anhydrase IX is highly expressed in hereditary nonpolyposis colorectal cancer. Cancer Epidemiol Biomarkers Prev. 2007, 16:1760-6.
169. Hynninen P, Vaskivuo L, Saarnio J. Expression of transmembrane carbonic anhydrases IX and XII in ovarian tumours. Histopathology. 2006, 49:594-602.
170. Chen J, Rocken C, Hoffmann J. Expression of carbonic anhydrase 9 at the invasion front of gastric cancers. Gut. 2005, 54:920-7.
171. Juhasz M, Chen J, Lendeckel U. Expression of carbonic anhydrase IX in human pancreatic cancer. Aliment Pharmacol Ther. 2003, 18:837-46.
172. Bartosova M, Parkkila S, Pohlodek K. Expression of carbonic anhydrase IX in breast is associated with malignant tissues and is related to overexpression of c-erbB2. J Pathol. 2002, 197:314-21.
173. Mayer A, Hockel M, Vaupel P. Carbonic anhydrase IX expression and tumor oxygenation status do not correlate at the microregional level in locally advanced cancers of the uterine cervix. Clin Cancer Res. 2005, 11:7220-5.
174. Pastorekova S, Parkkila S, Zavada J. Tumor-associated carbonic anhydrases and their clinical significance. Adv Clin Chem. 2006, 42:167-216.
175. Maseide K, Kandel RA, Bell RS. Carbonic anhydrase IX as a marker for poor prognosis in soft tissue sarcoma. Clin Cancer Res. 2004, 10:4464-71.
176. Trastour C, Benizri E, Ettore F. HIF-1alpha and CA IX staining in invasive breast carcinomas: prognosis and treatment outcome. Int J Cancer. 2007, 120:1451-8.
177. Loncaster JA, Harris AL, Davidson SE. Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix. Cancer Res. 2001, 61:6394-9.
178. Jonathan RA, Wijffels KI, Peeters W. The prognostic value of endogenous hypoxia-related markers for head and neck squamous cell carcinomas treated with ARCON. Radiother Oncol. 2006, 79:288-97.
179. Chia SK, Wykoff CC, Watson PH. Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma. J Clin Oncol. 2001, 19:3660-8.
180. Potter C, Harris AL. Hypoxia inducible carbonic anhydrase IX, marker of tumour hypoxia, survival pathway and therapy target. Cell Cycle. 2004, 3:164-7.
181. Haapasalo JA, Nordfors KM, Hilvo M. Expression of carbonic anhydrase IX in astrocytic tumors predicts poor prognosis. Clin Cancer Res. 2006, 12:473-7.
182. Koukourakis MI, Giatromanolaki A, Sivridis E. Hypoxia-regulated carbonic anhydrase-9 (CA9) relates to poor vascularization and resistance of squamous cell head and neck cancer to chemoradiotherapy. Clin Cancer Res. 2001, 7:3399-403.
183. Bui MH, Seligson D, Han KR. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res. 2003, 9:802-11.
184. Raval RR, Lau KW, Tran MG. Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Mol Cell Biol. 2005, 25:5675-86.
185. Tureci O, Sahin U, Vollmar E. Human carbonic anhydrase XII: cDNA cloning, expression, and chromosomal localization of a carbonic anhydrase gene that is overexpressed in some renal cell cancers. Proc Natl Acad Sci USA. 1998, 95:7608-13.
186. Barnett DH, Sheng S, Charn TH. Estrogen receptor regulation of carbonic anhydrase XII through a distal enhancer in breast cancer. Cancer Res. 2008, 68:3505-15.
187. Haapasalo J, Hilvo M, Nordfors K. Identification of an alternatively spliced isoform of carbonic anhydrase XII in diffusely infiltrating astrocytic gliomas. Neuro Oncol. 2008, 10:131-8.
188. Hynninen P, Hamalainen JM, Pastorekova S. Transmembrane carbonic anhydrase isozymes IX and XII in the female mouse reproductive organs. Reprod Biol Endocrinol. 2004, 2:73.
189. Karhumaa P, Parkkila S, Tureci O. Identification of carbonic anhydrase XII as the membrane isozyme expressed in the normal human endometrial epithelium. Mol Hum Reprod. 2000, 6:68-74.
190. Kivela A, Parkkila S, Saarnio J. Expression of a novel transmembrane carbonic anhydrase isozyme XII in normal human gut and colorectal tumors. Am J Pathol. 2000, 156:577-84.
191. Parkkila S, Parkkila AK, Saarnio J. Expression of the membrane-associated carbonic anhydrase isozyme XII in the human kidney and renal tumors. J Histochem Cytochem. 2000, 48:1601-8.
192. Kivela AJ, Parkkila S, Saarnio J. Expression of transmembrane carbonic anhydrase isoenzymes IX and XII in normal human pancreas and pancreatic tumours. Histochem Cell Biol. 2000, 114:197-204.
193. Kivela AJ, Parkkila S, Saarnio J. Expression of von Hippel-Lindau tumor suppressor and tumor-associated carbonic anhydrases IX and XII in normal and neoplastic colorectal mucosa. World J Gastroenterol. 2005, 11:2616-25.
194. Liao SY, Ivanov S, Ivanova A. Expression of cell surface transmembrane carbonic anhydrase genes CA9 and CA12 in the human eye: overexpression of CA12 (CAXII) in glaucoma. J Med Genet. 2003, 40:257-61.
195. Leppilampi M, Saarnio J, Karttunen TJ. Carbonic anhydrase isozymes IX and XII in gastric tumors. World J Gastroenterol. 2003, 9:1398-403.
196. Hilvo M, Baranauskiene L, Salzano AM. Biochemical characterization of CA IX, one of the most active carbonic anhydrase isozymes. J Biol Chem. 2008, 283:27799-809.
197. De Simone G, Supuran CT. Carbonic anhydrase IX: biochemical and crystallographic characterization of a novel antitumor target. Biochim Biophys Acta 2009
198. Whittington DA, Waheed A, Ulmasov B. Crystal structure of the dimeric extracellular domain of human carbonic anhydrase XII, a bitopic membrane protein overexpressed in certain cancer tumor cells. Proc Natl Acad Sci USA. 2001, 98:9545-50.
199. Pastorekova S, Zatovicova M, Pastorek J. Cancer-associated carbonic anhydrases and their inhibition. Curr Pharm Des. 2008, 14:685-98.
200. Pastorekova S, Ratcliffe PJ, Pastorek J. Molecular mechanisms of carbonic anhydrase IX-mediated pH regulation under hypoxia. BJU Int. 2008, 101:8-15.
201. Swietach P, Patiar S, Supuran CT. The Role of Carbonic Anhydrase 9 in Regulating Extracellular and Intracellular pH in Three-dimensional Tumor Cell Growths. J Biol Chem. 2009, 284:20299-310.
202. Morgan PE, Pastorekova S, Stuart-Tilley AK. Interactions of transmembrane carbonic anhydrase, CAIX, with bicarbonate transporters. Am J Physiol Cell Physiol 2007, 293:C738-48.
203. Svichar N, Waheed A, Sly WS. Carbonic anhydrases CA4 and CA14 both enhance AE3-mediated Cl-HCO3- exchange in hippocampal neurons. J Neurosci. 2009, 29:3252-8.
204. Gut MO, Parkkila S, Vernerova Z. Gastric hyperplasia in mice with targeted disruption of the carbonic anhydrase gene Car9. Gastroenterology. 2002, 123:1889-903.
205. Leppilampi M, Karttunen TJ, Kivela J. Gastric pit cell hyperplasia and glandular atrophy in carbonic anhydrase IX knockout mice: studies on two strains C57/BL6 and BALB/C. Transgenic Res. 2005, 14:655-63.
206. Pan P, Leppilampi M, Pastorekova S. Carbonic anhydrase gene expression in CA II-deficient (Car2-/-) and CA IX-deficient (Car9-/-) mice. J Physiol. 2006, 571:319-27.
207. Kivela AJ, Saarnio J, Karttunen TJ. Differential expression of cytoplasmic carbonic anhydrases, CA I and II, and membrane-associated isozymes, CA IX and XII, in normal mucosa of large intestine and in colorectal tumors. Dig Dis Sci. 2001, 46:2179-86.
208. Dorai T, Sawczuk IS, Pastorek J. The role of carbonic anhydrase IX overexpression in kidney cancer. Eur J Cancer. 2005, 41:2935-47.
209. Svastova E, Zilka N, Zat'ovicova M. Carbonic anhydrase IX reduces E-cadherin-mediated adhesion of MDCK cells via interaction with beta-catenin. Exp Cell Res. 2003, 290:332-45.
210. Parkkila S, Rajaniemi H, Parkkila AK. Carbonic anhydrase inhibitor suppresses invasion of renal cancer cells in vitro. Proc Natl Acad Sci USA. 2000, 97:2220-4.
211. Kim JY, Shin HJ, Kim TH. Tumor-associated carbonic anhydrases are linked to metastases in primary cervical cancer. J Cancer Res Clin Oncol. 2006, 132:302-8.
212. Halestrap AP, Price NT. The proton-linked monocarboxylate transporter (MCT) family: structure, function and regulation. Biochem J. 1999, 343:281-99.
213. Kirk P, Wilson MC, Heddle C. CD147 is tightly associated with lactate transporters MCT1 and MCT4 and facilitates their cell surface expression. EMBO J. 2000, 19:3896-904.
214. Su J, Chen X, Kanekura T. A CD147-targeting siRNA inhibits the proliferation, invasiveness, and VEGF production of human malignant melanoma cells by down-regulating glycolysis. Cancer Lett. 2009, 273:140-7.
215. Poole RC, Sansom CE, Halestrap AP. Studies of the membrane topology of the rat erythrocyte H+/lactate cotransporter (MCT1). Biochem J. 1996, 320:817-24.
216. Dimmer KS, Friedrich B, Lang F. The low-affinity monocarboxylate transporter MCT4 is adapted to the export of lactate in highly glycolytic cells. Biochem J. 2000, 350:219-27.
217. Gallagher SM, Castorino JJ, Philp NJ. Interaction of monocarboxylate transporter 4 with beta1-integrin and its role in cell migration. Am J Physiol Cell Physiol 2009, 296:C414-21.
218. Liang YX, He HC, Han ZD. CD147 and VEGF expression in advanced renal cell carcinoma and their prognostic value. Cancer Invest. 2009, 27:788-93.
219. Pinheiro C, Longatto-Filho A, Simoes K. The prognostic value of CD147/ EMMPRIN is associated with monocarboxylate transporter 1 co-expression in gastric cancer. Eur J Cancer. 2009, 45:2418-24.
220. Du ZM, Hu CF, Shao Q. Upregulation of caveolin-1 and CD147 expression in nasopharyngeal carcinoma enhanced tumor cell migration and correlated with poor prognosis of the patients. Int J Cancer. 2009, 125:1832-41.
221. Broer S, Broer A, Schneider HP. Characterization of the high-affinity monocarboxylate transporter MCT2 in Xenopus laevis oocytes. Biochem J. 1999, 341:529-35.
222. Lin RY, Vera JC, Chaganti RS. Human monocarboxylate transporter 2 (MCT2) is a high affinity pyruvate transporter. J Biol Chem. 1998, 273:28959-65.
223. Becker HM, Hirnet D, Fecher-Trost C. Transport activity of MCT1 expressed in Xenopus oocytes is increased by interaction with carbonic anhydrase. J Biol Chem. 2005, 280:39882-9.
224. Becker HM, Deitmer JW. Nonenzymatic proton handling by carbonic anhydrase II during H+-lactate cotransport via monocarboxylate transporter 1. J Biol Chem. 2008, 283:21655-67.
225. Sterling D, Reithmeier RA, Casey JR. A transport metabolon. Functional interaction of carbonic anhydrase II and chloride/bicarbonate exchangers. J Biol Chem. 2001, 276:47886-94.
226. Sterling D, Reithmeier RA, Casey JR. Carbonic anhydrase: in the driver's seat for bicarbonate transport. Jop. 2001, 2:165-70.
227. Li X, Alvarez B, Casey JR. Carbonic anhydrase II binds to and enhances activity of the Na+/H+ exchanger. J Biol Chem. 2002, 277:36085-91.
228. Li X, Liu Y, Alvarez BV. A novel carbonic anhydrase II binding site regulates NHE1 activity. Biochemistry. 2006, 45:2414-24.
229. Sonveaux P, Vegran F, Schroeder T. Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. J Clin Invest. 2008, 118:3930-42.
230. Hosoya K, Kondo T, Tomi M. MCT1-mediated transport of L-lactic acid at the inner blood-retinal barrier: a possible route for delivery of monocarboxylic acid drugs to the retina. Pharm Res. 2001, 18:1669-76.
231. Hunt TK, Aslam RS, Beckert S. Aerobically derived lactate stimulates revascularization and tissue repair via redox mechanisms. Antioxid Redox Signal. 2007, 9:1115-24.
232. Schneiderhan W, Scheler M, Holzmann KH. CD147 Silencing inhibits lactate transport and reduces malignant potential of pancreatic cancer cells in in-vivo and in-vitro models. Gut 2009, 58:1391-8.
233. Gallagher SM, Castorino JJ, Wang D. Monocarboxylate transporter 4 regulates maturation and trafficking of CD147 to the plasma membrane in the metastatic breast cancer cell line MDA-MB-231. Cancer Res. 2007, 67:4182-9.
234. Kroemer G, Pouyssegur J. Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell. 2008, 13:472-82.
235. Simons AL, Ahmad IM, Mattson DM. 2-Deoxy-D-glucose combined with cisplatin enhances cytotoxicity via metabolic oxidative stress in human head and neck cancer cells. Cancer Res. 2007, 67:3364-70.
236. Singh D, Banerji AK, Dwarakanath BS. Optimizing cancer radiotherapy with 2-deoxy-d-glucose dose escalation studies in patients with glioblastoma multiforme. Strahlenther Onkol. 2005, 181:507-14.
237. Kim W, Yoon JH, Jeong JM. Apoptosis-inducing antitumor efficacy of hexokinase II inhibitor in hepatocellular carcinoma. Mol Cancer Ther. 2007, 6:2554-62.
238. Passonneau JV, Lowry OH. Phosphofructokinase and the Pasteur effect. Biochem Biophys Res Commun. 1962, 7:10-5.
239. Hardie DG. Minireview: the AMP-activated protein kinase cascade: the key sensor of cellular energy status. Endocrinology. 2003, 144:5179-83.
240. Hardie DG. Metabolic control: a new solution to an old problem. Curr Biol 2000, 10:R757-9.
241. Russell RR, Bergeron R, Shulman GI. Translocation of myocardial GLUT-4 and increased glucose uptake through activation of AMPK by AICAR. Am J Physiol 1999, 277:H643-9.
242. Melillo G. Targeting hypoxia cell signaling for cancer therapy. Cancer Metastasis Rev. 2007, 26:341-52.
243. Semenza GL. Evaluation of HIF-1 inhibitors as anticancer agents. Drug Discov Today. 2007, 12:853-9.
244. Melillo G. Hypoxia-inducible factor 1 inhibitors. Methods Enzymol. 2007, 435:385-402.
245. Semenza GL. HIF-1 Inhibitors for cancer therapy: from gene expression to drug discovery. Curr Pharm Des. 2009, 15:3839-43.
246. Anderson KM, Jajeh A, Guinan P. Do intra-tumor alkaline micro-regions represent additional therapeutically privileged sites? Med Hypotheses. 2008, 70:1193-6.
247. Clarke MF, Dick JE, Dirks PB. Cancer stem cells-perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res. 2006, 66:9339-44.
248. Shackleton M, Quintana E, Fearon ER. Heterogeneity in cancer: cancer stem cells versus clonal evolution. Cell. 2009, 138:822-9.
249. Gupta PB, Chaffer CL, Weinberg RA. Cancer stem cells: mirage or reality? Nat Med. 2009, 15:1010-2.
250. Hill RP, Marie-Egyptienne DT, Hedley DW. Cancer stem cells, hypoxia and metastasis. Semin Radiat Oncol. 2009, 19:106-11.
251. Heddleston JM, Li Z, McLendon RE. The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype. Cell Cycle. 2009, 8:3274-84.
252. Wong P, Kleemann HW, Tannock IF. Cytostatic potential of novel agents that inhibit the regulation of intracellular pH. Br J Cancer. 2002, 87:238-45.
253. Thiry A, Supuran CT, Masereel B. Recent developments of carbonic anhydrase inhibitors as potential anticancer drugs. J Med Chem. 2008, 51:3051-6.
254. D'Ambrosio K, Vitale RM, Dogne JM. Carbonic anhydrase inhibitors: bioreductive nitro-containing sulfonamides with selectivity for targeting the tumor associated isoforms IX and XII. J Med Chem. 2008, 51:3230-7.
255. Ahlskog JK, Dumelin CE, Trussel S. In vivo targeting of tumor-associated carbonic anhydrases using acetazolamide derivatives. Bioorg Med Chem Lett. 2009, 19:4851-6.
256. Oosterwijk E, Bander NH, Divgi CR. Antibody localization in human renal cell carcinoma: a phase I study of monoclonal antibody G250. J Clin Oncol. 1993, 11:738-50.
257. Oosterwijk E. Carbonic anhydrase IX/G250/MN: a molecule too good to be true? BJU Int. 2008, 101:527-8.
258. Yin T, Yu S, Xiao L. Correlation between the expression of aquaporin 1 and hypoxia-inducible factor 1 in breast cancer tissues. J Huazhong Univ Sci Technolog Med Sci. 2008, 28:346-8.
259. Hayashi Y, Edwards NA, Proescholdt MA. Regulation and function of aquaporin-1 in glioma cells. Neoplasia. 2007, 9:777-87.
260. Saadoun S, Papadopoulos MC, Hara-Chikuma M. Impairment of angiogenesis and cell migration by targeted aquaporin-1 gene disruption. Nature. 2005, 434:786-92.
261. Baba M, Inoue M, Itoh K. Blocking CD147 induces cell death in cancer cells through impairment of glycolytic energy metabolism. Biochem Biophys Res Commun. 2008, 374:111-6.
262. Schlappack OK, Zimmermann A, Hill RP. Glucose starvation and acidosis: effect on experimental metastatic potential, DNA content and MTX resistance of murine tumour cells. Br J Cancer. 1991, 64:663-70.
263. Robey IF, Baggett BK, Kirkpatrick ND. Bicarbonate increases tumor pH and inhibits spontaneous metastases. Cancer Res. 2009, 69:2260-8.
264. Silva AS, Yunes JA, Gillies RJ. The potential role of systemic buffers in reducing intratumoral extracellular pH and acid-mediated invasion. Cancer Res. 2009, 69:2677-84.
265. Murakami T, Shibuya I, Ise T. Elevated expression of vacuolar proton pump genes and cellular PH in cisplatin resistance. Int J Cancer. 2001, 93:869-74.
266. Perez-Sayans M, Garcia-Garcia A, Reboiras-Lopez MD. Role of V-ATPases in solid tumors: importance of the subunit C. Int J Oncol. 2009, 34:1513-20.
267. Morimura T, Fujita K, Akita M. The proton pump inhibitor inhibits cell growth and induces apoptosis in human hepatoblastoma. Pediatr Surg Int. 2008, 24:1087-94.
268. Harguindey S, Arranz JL, Wahl ML. Proton transport inhibitors as potentially selective anticancer drugs. Anticancer Res. 2009, 29:2127-36.